Literature DB >> 11238627

A critical role for p38 mitogen-activated protein kinase in the maturation of human blood-derived dendritic cells induced by lipopolysaccharide, TNF-alpha, and contact sensitizers.

J F Arrighi1, M Rebsamen, F Rousset, V Kindler, C Hauser.   

Abstract

We investigated the involvement of mitogen-activated protein kinases (MAPKs) in the maturation of CD83(-) dendritic cells (DC) derived from human blood monocytes. Maturating agents such as LPS and TNF-alpha induced the phosphorylation of members of the three families of MAPK (extracellular signal-regulated kinase l/2, p46/54 c-Jun N-terminal kinase, and p38 MAPK). SB203580, an inhibitor of the p38 MAPK, but not the extracellular signal-regulated kinase l/2 pathway blocker PD98059, inhibited the up-regulation of CD1a, CD40, CD80, CD86, HLA-DR, and the DC maturation marker CD83 induced by LPS and TNF-alpha. In addition, SB203580 inhibited the enhancement of the allostimulatory capacity and partially prevented the down-regulation of FITC-dextran uptake induced by LPS and TNF-alpha. Likewise, SB203580 partially prevented the up-regulation of IL-1alpha, IL-1beta, IL-lRa, and TNF-alpha mRNA upon stimulation with LPS and TNF-alpha, as well as the release of bioactive TNF-alpha induced by LPS. DC maturation induced by the contact sensitizers 2,4-dinitrofluorobenzene and NiSO(4), as seen by the up-regulation of CD80, CD86, and CD83, was also coupled to the phosphorylation of p38 MAPK, and was inhibited by SB203580. The irritants SDS and benzalkonium chloride that do not induce DC maturation did not trigger p38 MAPK phosphorylation. Together, these data indicate that phosphorylation of p38 MAPK is critical for the maturation of immature DC. These results also suggest that p38 MAPK phosphorylation in DC may become useful for the identification of potential skin contact sensitizers.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238627     DOI: 10.4049/jimmunol.166.6.3837

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  98 in total

Review 1.  Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances.

Authors:  Gwendalyn J Randolph; Guzman Sanchez-Schmitz; Veronique Angeli
Journal:  Springer Semin Immunopathol       Date:  2005-01

2.  Pore-formation by adenylate cyclase toxoid activates dendritic cells to prime CD8+ and CD4+ T cells.

Authors:  Martina Svedova; Jiri Masin; Radovan Fiser; Ondrej Cerny; Jakub Tomala; Marina Freudenberg; Ludmila Tuckova; Marek Kovar; Gilles Dadaglio; Irena Adkins; Peter Sebo
Journal:  Immunol Cell Biol       Date:  2015-10-06       Impact factor: 5.126

Review 3.  Role of bioactivation in drug-induced hypersensitivity reactions.

Authors:  Joseph P Sanderson; Dean J Naisbitt; B Kevin Park
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

Review 4.  Dendritic cells and contact dermatitis.

Authors:  Yoshinori Sasaki; Setsuya Aiba
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

5.  Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides.

Authors:  Klaus Zwiorek; Carole Bourquin; Julia Battiany; Gerhard Winter; Stefan Endres; Gunther Hartmann; Conrad Coester
Journal:  Pharm Res       Date:  2007-10-03       Impact factor: 4.200

Review 6.  Transcription factors in the control of dendritic cell life cycle.

Authors:  Arpita S Bharadwaj; Devendra K Agrawal
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  Selective regulation of CD40 expression in murine dendritic cells by thiol antioxidants.

Authors:  Norifumi Iijima; Yoshiki Yanagawa; Kazuya Iwabuchi; Kazunori Onoé
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

8.  Per a 10 protease activity modulates CD40 expression on dendritic cell surface by nuclear factor-kappaB pathway.

Authors:  C Goel; N Kalra; B S Dwarakanath; S N Gaur; N Arora
Journal:  Clin Exp Immunol       Date:  2015-05       Impact factor: 4.330

9.  Targeting MARCO can lead to enhanced dendritic cell motility and anti-melanoma activity.

Authors:  Norimasa Matsushita; Hiroshi Komine; Annabelle Grolleau-Julius; Shari Pilon-Thomas; James J Mulé
Journal:  Cancer Immunol Immunother       Date:  2010-01-08       Impact factor: 6.968

10.  Role of hypoxia-inducible factor 1, α subunit and cAMP-response element binding protein 1 in synergistic release of interleukin 8 by prostaglandin E2 and nickel in lung fibroblasts.

Authors:  Kelly A Brant; James P Fabisiak
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.